GlobeImmune Stock Forecast, Price & News

-0.09 (-15.75 %)
(As of 07/22/2021 03:56 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume4,927 shs
Average Volume17,364 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GBIM News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeImmune and its competitors with MarketBeat's FREE daily newsletter.

GlobeImmune logo

About GlobeImmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.


GlobeImmune Inc.
GlobeImmune Inc.
October 24, 2019 |  www.barrons.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.46 out of 5 stars

Medical Sector

1764th out of 2,216 stocks

Pharmaceutical Preparations Industry

747th out of 866 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

GlobeImmune (OTCMKTS:GBIM) Frequently Asked Questions

What stocks does MarketBeat like better than GlobeImmune?

Wall Street analysts have given GlobeImmune a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GlobeImmune wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were GlobeImmune's earnings last quarter?

GlobeImmune, Inc. (OTCMKTS:GBIM) released its quarterly earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.12. The biopharmaceutical company earned $0.94 million during the quarter.
View GlobeImmune's earnings history

How has GlobeImmune's stock price been impacted by Coronavirus (COVID-19)?

GlobeImmune's stock was trading at $0.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GBIM stock has increased by 405.5% and is now trading at $0.5055.
View which stocks have been most impacted by COVID-19

Who are GlobeImmune's key executives?

GlobeImmune's management team includes the following people:
  • Mr. C. Jeffrey Dekker, Pres, VP of Fin., Treasurer & Sec. (Age 56, Pay $200.05k)
  • Dr. Richard C. Duke, Scientific Founder & Member of Scientific Advisory Board
  • Dr. Donald Bellgrau, Scientific Founder & Chairman of The Scientific Advisory Board
  • Mr. Thomas A. Keuer, Acting Head of Manufacturing Operations (Age 62)
  • Dr. Allen L. Cohn M.D., Exec. Director Clinical Devel. (Age 63)

Who are some of GlobeImmune's key competitors?

What other stocks do shareholders of GlobeImmune own?

What is GlobeImmune's stock symbol?

GlobeImmune trades on the OTCMKTS under the ticker symbol "GBIM."

How do I buy shares of GlobeImmune?

Shares of GBIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlobeImmune's stock price today?

One share of GBIM stock can currently be purchased for approximately $0.51.

How many employees does GlobeImmune have?

GlobeImmune employs 2 workers across the globe.

What is GlobeImmune's official website?

The official website for GlobeImmune is www.globeimmune.com.

Where are GlobeImmune's headquarters?

GlobeImmune is headquartered at 1450 INFINITE DRIVE, LOUISVILLE CO, 80027.

How can I contact GlobeImmune?

GlobeImmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-625-2700 or via email at [email protected]

This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.